Stopping rules in First entry into human studies

Alain Patat, Henri Caplain, Yves Donazzolo, Stephan Chalon, Michel Sibille Club Phase 1 Working Party

• To improve decision making in dose escalation as requested by regulatory authorities after TGN 1492 incident on 13 MAR 2006 in the UK

• Needs:

- Standardisation of quotation...then accurate and relevant «Grading»
- Clinically relevant & accepted «Stopping rules»

WHY


To-day : Current guidelines available

Nothing relevant and accepted fitting well to healthy subject participating in FIHs

- WHO Recommendations for grading Acute & subacute toxic effects WHO Handbook for reporting results of cancer treatment (1979) → Oncology
- NCI Common Terminology for Adverse Events (CTCAE v3 Aug 2006) → Oncology
- **3.** NIH Division of AIDS (Dec 2004) : Table for grading the severity of adult and pediatric adverse events
- **4. FDA** Guidance for Industry (Sept 2007) : *Toxicity grading scale for adult and adolescent volunteers enrolled in preventive vaccine clinical trials*

Club Phase 1 Goal(s)

- Method of quotation clinical AEs and non clinical abnormalities (vital signs, ECG & lab tests)
- **2.** Applications (thresholds/grades)
- 3. Method supporting stopping rules determination Individual level Cohort level (including MTD)



- FIMs dose escalation studies single & multiple dose
- Healthy (young) subjects as a first step

What is an Adverse Event (1)

Adverse Event: ICH def

- « any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarly have to have a causal relationship to this treatment»
- Any spontaneously reported or observed AE → to be collected

Is the Event Related ? (2)

- Investigator judgement: « unrelated, unlikely, possible, probable, (likely) or definite »
- Final judgement / coding : binary process (related or not related)
- Low imputability power due to small number of subjects →
 - Clear proof of intercurrent disease: non-related
 - If not => related

Types and Kinds of Event (3)

- Two types and kinds:
 - Clinical AEs (discontinuous variables) → quotation directly derived from observed severity or daily life consequences
 - Non-clinical «abnormalities» (continuous numerical variables) → quotation derived from an «estimated likelihood» of risk or consequence → quotation based on thresholds to be determined

Proposed quotation

- 1. Responsible: Investigator
- 2. Criteria: Severity
- **3**. Grading: use the NIH/FDA 4-level scales:
 - 1. Grade 1: mild: Does not interfere with activity
 - 2. Grade 2: moderate: Interferes with activity; no ttt, excepted acetaminophen (limited amount)
 - **3**. Grade 3: severe: Prevents daily activity or requires ttt (or medical intervention FDA)
 - 4. Grade 4: life-threatening: Emergency room visit or disabling or hospitalization

Intensity	1 Mild	2 Moderate	3 Severe	4 Potentially life- threatening
General definition	Does not interfere with activity	Interferes with activity, no treatment except acetaminophen	Prevents daily activity or requires treatment	Emergency room visit or hospitalization
Possible modulations based on:	number of episodes and/or	duration of symptoms and/or	associated malaise or	general effects.
Headache	Transient	Interferes with activity, no treatment except acetaminophen Several hours but less <12 hours.	Prevents daily activity or requires treatment > 12 h, presence during the night.	Emergency room visit or hospitalization
Pain (whatever location)	Transient	Interferes with activity, no treatment except acetaminophen Several hours but less <12 hours.	Prevents daily activity or requires treatment > 12 h, presence during the night.	Emergency room visit or hospitalization
Malaise/syncope ®	Does not interfere with activity	Interferes with activity, no treatment 10ème journée Club Pha	Syncope®, or prevents daily activity, or requires treatment	Repeated syncopes. Emergency room visit or hospitalization

Intensity	1 Mild	2 Moderate	3 Severe	4 Potentially life- threatening
General definition	Does not interfere with activity	Interferes with activity, no treatment except acetaminophen	Prevents daily t activity or requires treatment	Emergency room visit or hospitalization
Possible modulations based on:	number of episodes and/or	<i>duration of symptoms</i> <i>and/or</i>	associated malaise or	general effects.
Asthenia	Does not interfere with usual and social activity	Interfere with usual and social activity, no treatment	Prevents daily activity or requires treatment	Emergency room visit or t hospitalization
Cognitive disturbances Concentration or memory disorder	Idem	Idem	Idem	Idem
Confusion or disorientation or attention disorder	Idem	Idem	Idem	Idem
Somnolence/ drowsiness	Idem	Idem	Idem	Idem
Dizziness or vertigo or light headedness	Idem	Idem	Idem	Idem
		10ème journée Club Phase		11

Intensity	1 Mild	2 Moderate	3 Severe	4 Potentially life- threatening
General definition	Does not interfere with activity	Interferes with activity, no treatment except acetaminophen	Prevents daily activity or requires treatment	Emergency room visit or hospitalization
Possible modulations based on:	number of episodes and/or	duration of symptoms and/or	associated malaise or	general effects.
Nausea/meteorism or dyspepsia	Keep normal intake	Intake significantly decreased	No intake. Requires treatment	Parenteral support t or hospitalization
Vomiting	1 episode	2 to 4 episodes/day or 2/day x 2 days	> 4 episodes per day or 2 or more per day prolonged on several days	Parenteral support or hospitalization
FDA •••	1-2	>2	IdemPrevents daily activity or requires treatment	Parenteral support or hospitalization
Diarrhea	Increase of 2-3 stools/day over normal pre- study flow	Increase of 4-5 stools/day or moderate cramping	Increase of 6-8 or severe cramping or incontinence	Increase > 8 or Bloody diarrhea or parenteral support
FDA***	2-3 loose stools	4-5 loose stools 10ème journée Club Phase	6 or more watery _e stools	Parenteral support or hospitalization ₂

Threshold(s) ? Relevant method

Major difficulty and weakness of previous guidelines (FDA-NIH controversy): no method have been described and used !!!!

- Two possible approaches:
 - Existing & recognized threshold or rules:
 - Disease definition (diabete, HTA, anemia)
 - Published rule: Hy's law
 - Use a relevant method to determine the threshold between spontaneous variation and potentially clinically significant abnormality in healthy subjects

Grade I Threshold ?

«Combined method» based on:

is basically designed to define the grade 1 thresholds.

Table 2: Determination of the "Grade I threshold" usingCombined Method:

Healthy subject database* (unpublished data, see also 9)

Some examples ...

Parameters LAB	Unit	Reference Values** (Lower/ Upper limit of Normal ranges)	Reference changes Decrease: (-) Increase (+) Median value*	Relative values to NR Lower Higher	
ALT	IU/L	10 - 58	(+10)	NA +1.3	
AST	IU/L	10 - 43	(+9)	NA +1.2	
Bilirubin	µmol/L	5 – 27	(+12)	NA +1.3	
Creatinin	µmol/L	78 – 113	(+15)	+1.1	
Potassium	mmol/L	3.5 – 4.9	(-0.2) (+0.8)	-0.9 +1.1	
СРК	IU/L	53 - 400	(+72) mean : - 29	+1.2	
Neutrophils	giga/L	1.7 - 6.5	(- 0.5) (+ 1.8)	- 0.7 +1.3	
Platelets	giga/L	153 - 324	(-20)	- 0.8	

 * These data are applicable for young male subject. On some parameters, an adaptation is required for females or elderly or black people.
 ** The reference values (normal ranges) shoud not necessarely be used as inclusion criteria. *** Due to frequency of Gilbert disease in young men the inclusion limit is 27.

Grade 2, 3, 4 Thresholds ?

- Except for some cases for ex Hy's law, nothing is recognized to define such tresholds !!!
- Proposal: consensus approach
 - CPI seniors : investigators & sponsors consensus
 - Consider CTCAE, WHO, FDA and NIH grades
 - Submit proposals for agreement internal submission
 - Publish & collect remarks, criticizisms and finalize



- 1. Lab
- 2. ECG
- 3. Vital sign
- 4. ...

Table 3: Lab abnormalities grading

- Conditions:
 - Accurate sampling and assay conditions
 - Any abnormality requires a control before validation
 - U(L)LN = upper (lower) limit of laboratory normal range of the local lab of the Clinical Pharmacology Unit
 - Association to clinical symptoms or concomitant changes of other lab parameters induces an upgrading

Table 3: Lab abnormalities grading

Liver

Intensity	1 Mild	2 Moderate	3 Severe
ALT	1.3/3 ULN	3/5 ULNR*	5/10 ULNR
FDA ⁰⁰⁰	1.1/2.5	2.6/5	5/10
NIH	1.25/2.5	205/5	5/10
AST	1.2/3ULN	3/5 ULN*	5/10
$FDA^{\circ\circ\circ}$	1.1/2.5ULN	2.6/5ULN*	5/10ULN*
Bilirubin	1.3/2ULN if change from baseline > 10 mmol/L	2/2.5*	2.5/3*
FDA ⁰⁰⁰ if ALT nl.	1.1/1.5ULN	1.6/2*	2/3*
Alkaline phosphatase	1.1/2ULNR	2.1/3	3.1/10
$FDA^{\circ\circ\circ}$	1.1/2ULNR	2.1/3	3.1/10
<u>Hy's Law (10)</u>	10ème journée C	lub Phase I	ALT>3ULN and Bili>2ULN 21

Intensity	1 Mild	2 Moderate	3 Severe
Creatinin	1.1/1.5 ULNR	1.5/2 ULNR*	2/2.5 ULNR
FDA ⁰⁰⁰ mg	1.5/1.7	1.8/2	2.1/2.5
NIH	101/1.3	1.4/1.8	1.9/3.4
Neutrophils decrease Caucasian	LLN to 0.7LLN and decrease >0.5	0.7LLNR to 1.0 giga	< 1.0
FDA°°°ALL	2.5/3.5	1.5/2.4	1/1.4
Black Giga/L	LLN to 0.7LLN and decrease >0.5	0.7LLNR to 0.8 giga	< 0.8
CPK Assuming in housed conditions and no physical exercise	450/1000 or 1.1/2.5ULN	1000/2000 or 2.5 to 5ULN	2000/5000 or 5 to 10 ULNR
$FDA^{\circ\circ\circ}$	1.25/1.5ULN	1.6/3	3.1/10
NIH	3/5.9	6/9.9	10/19.9

Intensity	1 Mild	2 Moderate	3 Severe	4 Life-threatening
Potassium: Hypokalemia if sampling	LLNR to -0.9 LLNR or 3.4 to 3.1 mEq and decrease	No relevance	ECG signs or <0.9LLNR or 3mEq and below	<2 or dysrythmias or muscle weakness or ileus of gut
without	> 0.2 mEq			
tourniquet FDA ⁰⁰⁰	3.5/3.6	3.3/3.4	3.1/3.2	
NIH	3.4/3	2.9/2.5	2.4/2	
Hyperkalemia if sampling without	ULNR to 1.1 ULNR or 5 to 5.5 mEq and increase	No relevance	ECG signs or >1.1ULNR or sup to 5.5mEq	>7 or dysrythmias or muscle weakness
tourniquet	>0.8mEq			
FDA ⁰⁰⁰	5.1/5.2	5.3/5.4	5.5/5.6	
NIH	5.6/6	6.1/6.5	6.6/7	
Glucose: Hypoglycemia mmol/L	LLNR to 0.8 LLNR or LLNR to 3mmol/L and decrease over 0.5		< 3 mmol/L or clinical signs	Clinical signs
FDA ⁰⁰⁰	3.5/3.8	3/3.4	2.5/2.9	<2.5
Hyperglycemia mmol/L - fasting	ULNR to 1.1ULNR and increase over 1	1.1ULNR to 7mmol	> 7	Insulin requirement
FDA ⁰⁰⁰	5.6/6.1	6.2/6.9	>6.9	Insulin requirement/ hyperosmolar coma



* FDA draft guidance:

The "appearance of worsening of fatigue, nausea, vomiting, fever, rash, eosinophilia or right upper quadrant pain or tenderness" or the "association to INR superior to 1.5" induces an upgrading (2).

** Trend: significant & fast worsening of results also induces an upgrading



If potential PD effect:

ie decreasing the glucose level with an antidiabetics will not be considered as a worrying AE but as a beneficial effect and the accepted lower limit of the glycemia will be very different

increasing aPTT with an anticoagulant drug is a beneficial effect and therefore threshold may be greater (3 ULNR used as stopping rule)

	Mild	Moderate	Severe	Life-threatening
Haemoglobin decrease in male g/dL *	LLNR to 12 and decrease >1.5	11.9 to 10	< 9.5	Clinical signs Take care of blood amount sampling
FDA ⁰⁰⁰	12.5/13.5	10.5/12.4	8.5/10.4	<8.5
FDA ⁰⁰⁰ change	<1.5	1.6/2	2.1/5	>5
Haemoglobin decrease in female g/dL	LLNR to 11 and decrease > 2	10.9 to 9.5	< 9.5	Clinical signs
$FDA^{\circ\circ\circ}$	11/12	9.5/10.9	8/9.4	<8
FDA ⁰⁰⁰ change	<1.5	1.6/2	2.1/5	>5
Eosinophils**	620/750 or 1.3/1.5 ULN	750/1500 or 1.5/3ULN	>1500 or >5ULN	Clinical signs
FDA ⁰⁰⁰ cell/mm3	650/1500	1500/500 0	>5000	Clinical signs
Platelet Giga/L Assuming lack of platelet cluster	125/100	100/75	75/25 or minor bleeding	<25 or major bleeding
$FDA^{\circ\circ\circ}$	125/140	100/124	25/99	<25

ECG	Mild	Moderate	Severe	Life-threatening
PR interval msec	220/250 and increase from baseline > 20	>250	Mobitz 2 or syncope	Complete AV block
NIH	210/250	>250	Mobitz 2 or ventricular pause > 3 sec	Complete AV block
QTc interval msec young male using the most accurate QTc formula	460/479 and increase superior to 40	476/499	Exceed 500 or QTc over 450 and increase > to 60	Ventricular dysrhythmias or torsade de pointe
QTc interval Female or elderly people	20msec addition Threshold moved to 470			

Heart Rate	Mild	Moderate	Severe	Life-threatening
Bradycardia bpm	NA	< 40 and decrease from baseline exceeds minus 20	Clinical lack of tolerability and/or ECG abnormalities	Emergency room visit or Hospitalization Arrythmias or conduction disorder
FDA	50-54	45-49	< 45	
Tachycardia bpm	101/115	116/130	>130 or dysrythmias (ventricular)	Emergency room visit or hospitalization Dysrrythmias or
FDA	100/115	116/130	>130	

Supine blood pressure mmHg	Mild	Moderate	Severe	Life-threatening
Systolic increase	140/150 and > +20	150/160	>160 or headache	Emergency room visit or hospitalization
Diastolic increase	95/99 and >+10	100/110	>110	Emergency room visit or hospitalization
FDA ⁰⁰⁰ SBP DBP	141/150 91/95	151/155 96/100	>155 >100	
NIH SBP DBP	140/159 99/90	160/179 100/109	>180 >110	
Systolic decrease	90/80 and variation from baseline over minus 25	80/70	<70 or symptomatic	
Postural hypotension Systolic BP mmHg	Decrease > to 20, association to reflex tachycardia	Cannot stay standing.	Syncope or prevents daily activity, or requires treatment	Repeated syncopes. Emergency room visit or hospitalization
Fever				
<i>"central"</i> adapt values to the type of measure	38/38.4 °C 100.4/101.1°F	38.5/39.4 °C 101.2/102/9 °F 10ème journée Club	39.5/40.4 °C 103.1/104.7 °F Phase I	>40.5 °C >104.8 °F

Decision process Stopping rules

Difficulty due to conflict-of-interest:

- Subject protection → caution
- Learning on drug \rightarrow pushing dose escalation

Decision process Stopping rules

Three criteria will lead the process

- **AE Grades**
- Number of similar AEs
- Drug relationship :Active or Placebo

Stopping Rules : Individual level

• if any event of grade equal or greater than 3

Stopping rules at cohort level

- **1.** No adverse event \rightarrow dose escalation
- 2. $AE(s) \rightarrow grading$
 - if intensity $< 3 \rightarrow$ dose esc.
 - if intensity = or > 3
 - Stop treatment of the(se) subject(s)
 - Unblinding (sponsor resp.): limited to the grade 3 subject(s).

Stopping rules at a cohort level

- AE severity equal or greater than 3 : Unblind
 - Only placebo \rightarrow dose esc.
 - Placebo <u>and</u> active \rightarrow dose adaptation
 - No placebo & frequency < 50% → dose adaptation
 - No placebo & frequency = or > 50% → stop
 & MTD qualification

Stopping rules at a cohort level (3)

Dose Adaptations:

- 50% or less or more
- Predefined criteria:

PK, supraproportionality, PD, AE of special interest

Stopping rules at a cohort level (4)

- Adaptations: Grade 2 or 3 to support stopping rules
- Ambiguity of PD effect \rightarrow need two different levels
- Grade « 2+ » = upgrading
 - * magnitude of variation from baseline
 - * trend (big or fast increase/decrease)
 - * association to clinical signs
 - * association to other abnormality (ie Hy's law)